CTRI/2022/02/040103招募中未知
A Randomized, Open Label, Multicenter, Two-treatment, Single-period, Multiple Dose, Parallel, Steady State Bioequivalence Study of Paliperidone Palmitate (3-month) Extended Release Injectable Suspension for intramuscular use 546 mg (350 mg Paliperidone) (Pharmathen S.A., Greece) compared to TREVICTA�® 350 mg Prolonged Release Suspension for injection (Janssen-Cilag International NV, Belgium) in adult schizophrenic patients.
试验速览
- 阶段
- 未知
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Male or non-pregnant, non-lactating females aged 18-65 years (inclusive) having a documented clinical diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V).
- •2.Written informed consent for participation in the study by the patient and patientââ?¬•s legal acceptable representative (LAR) and willing to adhere to protocol requirements.
- •3.Patients having BMI between 18-35 kg / m2 and at least 50 kg weight for male patients and 48 kg for female patients.
- •4.Patients who at screening are at a stable regimen of oral Paliperidone or Risperidone therapy or who are already receiving Paliperidone palmitate 156 mg (100 mg Paliperidone) extended release injectable suspension and who at randomization are receiving a stable regimen of 156 mg (100 mg Paliperidone) of monthly paliperidone palmitate extended release suspension via the intramuscular route.
- •5.Patients who are clinically stable and not hospitalized for exacerbation of psychiatric symptoms for at least 3 months before randomization.
- •6.Patients having Clinical Global Impression scale score of ââ?°Â¤ 4 at both screening and Baseline visits.
- •7.Patients not having any significant diseases or clinically significant abnormal findings except schizophrenia during screening
- •8.Adequate organ and bone marrow function at screening and randomization defined by: Bone marrow function:
- •a)Total white blood cell countââ?°Â¥ 4000/mm3
- •b)ANC ââ?°Â¥1500/mm3
- •c)Platelet count ââ?°Â¥ 100,000/mm3
- •d)Hemoglobin ââ?°Â¥ 9gm/dl
- •Hepatic function: Bilirubin <1.5 X ULN
- •AST & ALT <5 X ULN
- •Renal function: Creatinine clearance more than or equal 80 mL per min (Calculated based on Cockcroft-Gault formula)
- •9.Patients able to comply with study procedures in the opinion of the investigator.
- •10.In case of Male patients: Either partner or patient must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during the study and up to 90 days after the last PK sample collection. Cessation of birth control after this point should be discussed with a responsible physician.
- •11.Women of non child bearing potential with documented evidence of hysterectomy / bilateral salpingectomy / bilateral oophorectomy at least 6 months prior to IMP administration) or postmenopausal for at least 12 consecutive months.
- •Women of child bearing potential must have negative pregnancy test at screening visit and before randomization and must agree to use an effective method of avoiding pregnancy (including oral, transdermal or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to IMP administration] sexual partner) for at least 4 weeks prior to IMP administration, during the study and up to 90 days after the last dose of IMP. Cessation of birth control after this point should be discussed with a responsible physician
- •Note: It is the investigatorââ?¬•s responsibility to ensure that the above points regarding an effective method of avoiding pregnancy are discussed with the patient/LAR in detail and patient agrees with this and this is d
排除标准
- •1.Patients with known hypersensitivity/ intolerance to study drug or any other component of the drug or intolerance to oral paliperidone/risperidone prior to screening.
- •2.Patients with a history of Neuroleptic Malignant Syndrome (NMS) while on treatment with antipsychotics.
- •3.History or presence of circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with use of drugs that prolong QTc interval, including: bradycardia, cardiac arrhythmias, hypokalemia or hypomagnesemia, concomitant use of other drugs that known to prolong the QTc interval, and prolonged QT interval (QTc > 450 msec in male patients or QTc > 470 msec in female patients, QTc interval to be calculated with Bazettââ?¬•s Formula, at screening and randomization.
- •6.Patients with concurrent condition of Parkinsons disease except for drug-induced extrapyramidal syndrome. Patients with history or presence of tardive dyskinesia. Patients with cognitive and motor impairment.
- •7.Patients with concomitant treatment with hepatic enzyme inhibitors (including fluoxetine or paroxetine) or medications known to interact with study medication within 2 weeks of the first injection of study medication.
- •Note: If the patient was on any of these drugs, sufficient wash out period (of at least 5 half- lives) must have elapsed since the last dose of such drug and the first dose of study medication.
- •8.Treatment with any of the following therapies:
- •Ã¢â?¬Â¢Injection of risperidone long acting injection within 6 weeks before randomization.
- •Ã¢â?¬Â¢Electroconvulsive therapy within 3 months prior to screening.
- •Ã¢â?¬Â¢Clozapine within 3 months before screening
- •9.Presence of syncope or orthostatic hypotension (defined as systolic blood pressure decrease of at least 30 mmHg or a diastolic blood pressure decrease of at least 20 mmHg within one to three minutes of standing up).
- •10.Patients with uncontrolled hypertension (systolic BP more than or equal to 150 mmHg/diastolic BP more than or equal to 100 mmHg).
- •11.Patients with known cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia and treatment with antihypertensive medications).
- •12.Patients with inadequate mass in the deltoid regions to receive the intramuscular drug injection.
- •13.Patients with severe hepatic impairment based on the Child-Pugh classification (Child-Pugh category C).
- •14.Patients with a history of alcohol or drug-dependence as per DSM-V criteria during the 6-month period prior to screening.
- •15.Donation of blood (ââ?°Â¥ 1 unit or 350 mL) within 90 days prior to receiving the first dose of study medication or during the study.
- •16.Patient attempted suicide within 12 months before screening or current thoughts of suicide (suicidal ideation) or violent tendencies/ behavior as clinically assessed by the investigator.
- •17.Patients found positive for HIV, Syphilis, Hepatitis B surface antigen or Hepatitis C antibody at screening.
- •18.A history of granulocytopenia, agranulocytosis or myeloproliferative disorders (drug-induced or idiopathic).
- •19.Patient positive on Breath alcohol analyzer test at the time of visit at screening and/or baseline.
- •20.Treatment with any investigational drug in the last 3 months (or 5 half-lives, whichever is longer
研究者
相似试验
已完成
不适用
Bioequivalence study of clozapine in schizophrenic patientsCTRI/2014/04/004524Remedica Ltd24
已完成
不适用
A Study of Doxorubicin Hydrochloride Liposome Injection in Patients with Ovarian Cancer.CTRI/2018/08/015266Celerity Pharmaceuticals LLC76
已完成
不适用
A Study of Doxorubicin Hydrochloride Injection in Patients with Breast CancerCTRI/2018/08/015325Celerity Pharmaceuticals LLC68
进行中（未招募）
Unknown
To assess the bioequivalence and safety of paliperidone 100mg prolonged release suspension for injection of Sun Pharmaceutical Industries Ltd, India in schizophrenic patientsCTRI/2023/09/058099Sun Pharmaceutical Industries Limited,
进行中（未招募）
不适用
Bioequivalence (BE) Study of Pazopanib in subjects with Advanced renal cell carcinoma.CTRI/2020/11/029079Alvogen PB RD LLC